334.75 USD
-0.08 (-0.02%)
334.8 USD
+0.05 (+0.01%)
Taking everything into account, SWAV scores 6 out of 10 in our fundamental rating. SWAV was compared to 186 industry peers in the Health Care Equipment & Supplies industry. SWAV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SWAV is growing strongly while it is still valued neutral. This is a good combination! These ratings could make SWAV a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year SWAV was profitable.
SWAV had a positive operating cash flow in the past year.
In multiple years SWAV reported negative net income over the last 5 years.
In multiple years SWAV reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of SWAV (9.95%) is better than 93.23% of its industry peers.
SWAV's Return On Equity of 21.76% is amongst the best of the industry. SWAV outperforms 95.31% of its industry peers.
SWAV has a better Return On Invested Capital (8.81%) than 88.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROIC | 8.81% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 20.76%, SWAV belongs to the best of the industry, outperforming 94.79% of the companies in the same industry.
SWAV has a better Operating Margin (20.52%) than 94.27% of its industry peers.
Looking at the Gross Margin, with a value of 86.99%, SWAV belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
In the last couple of years the Gross Margin of SWAV has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
2. Health
2.1 Basic Checks
SWAV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SWAV has more shares outstanding
SWAV has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SWAV is higher compared to a year ago.
2.2 Solvency
SWAV has an Altman-Z score of 10.26. This indicates that SWAV is financially healthy and has little risk of bankruptcy at the moment.
SWAV has a better Altman-Z score (10.26) than 86.98% of its industry peers.
The Debt to FCF ratio of SWAV is 4.41, which is a neutral value as it means it would take SWAV, 4.41 years of fcf income to pay off all of its debts.
SWAV has a Debt to FCF ratio of 4.41. This is amongst the best in the industry. SWAV outperforms 82.81% of its industry peers.
SWAV has a Debt/Equity ratio of 0.97. This is a neutral value indicating SWAV is somewhat dependend on debt financing.
SWAV's Debt to Equity ratio of 0.97 is on the low side compared to the rest of the industry. SWAV is outperformed by 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 10.26 |
ROIC/WACC0.94
WACC9.36%
2.3 Liquidity
SWAV has a Current Ratio of 13.81. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.81, SWAV belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
SWAV has a Quick Ratio of 12.61. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.61, SWAV belongs to the best of the industry, outperforming 97.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 |
3. Growth
3.1 Past
SWAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.34%, which is quite good.
SWAV shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.44%.
The Revenue has been growing by 126.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
3.2 Future
SWAV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.56% yearly.
Based on estimates for the next years, SWAV will show a very strong growth in Revenue. The Revenue will grow by 20.10% on average per year.
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
SWAV is valuated quite expensively with a Price/Earnings ratio of 78.21.
Based on the Price/Earnings ratio, SWAV is valued a bit cheaper than the industry average as 67.19% of the companies are valued more expensively.
SWAV is valuated expensively when we compare the Price/Earnings ratio to 26.92, which is the current average of the S&P500 Index.
SWAV is valuated quite expensively with a Price/Forward Earnings ratio of 53.09.
SWAV's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SWAV is cheaper than 68.75% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.46. SWAV is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 |
4.2 Price Multiples
67.19% of the companies in the same industry are more expensive than SWAV, based on the Enterprise Value to EBITDA ratio.
75.00% of the companies in the same industry are more expensive than SWAV, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.65 | ||
| EV/EBITDA | 66.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SWAV does not grow enough to justify the current Price/Earnings ratio.
SWAV has a very decent profitability rating, which may justify a higher PE ratio.
SWAV's earnings are expected to grow with 24.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%
5. Dividend
5.1 Amount
No dividends for SWAV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
334.75
-0.08 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners10.85%
Inst Owner Change0%
Ins Owners5.23%
Ins Owner Change0%
Market Cap12.57B
Revenue(TTM)787.98M
Net Income(TTM)163.55M
Analysts53.75
Price Target330.75 (-1.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.32%
Min EPS beat(2)27.98%
Max EPS beat(2)44.66%
EPS beat(4)3
Avg EPS beat(4)18.35%
Min EPS beat(4)-12.88%
Max EPS beat(4)44.66%
EPS beat(8)7
Avg EPS beat(8)24.97%
EPS beat(12)11
Avg EPS beat(12)73.56%
EPS beat(16)13
Avg EPS beat(16)54.46%
Revenue beat(2)1
Avg Revenue beat(2)1.53%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)3.29%
Revenue beat(8)5
Avg Revenue beat(8)2.94%
Revenue beat(12)9
Avg Revenue beat(12)5.4%
Revenue beat(16)13
Avg Revenue beat(16)8.23%
PT rev (1m)2.57%
PT rev (3m)25.91%
EPS NQ rev (1m)-2.66%
EPS NQ rev (3m)-2.74%
EPS NY rev (1m)6.44%
EPS NY rev (3m)16.18%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 | ||
| P/S | 15.95 | ||
| P/FCF | 75.65 | ||
| P/OCF | 63.5 | ||
| P/B | 16.72 | ||
| P/tB | 20.26 | ||
| EV/EBITDA | 66.43 |
EPS(TTM)4.28
EY1.28%
EPS(NY)6.31
Fwd EY1.88%
FCF(TTM)4.42
FCFY1.32%
OCF(TTM)5.27
OCFY1.57%
SpS20.99
BVpS20.03
TBVpS16.52
PEG (NY)2.17
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROCE | 10.42% | ||
| ROIC | 8.81% | ||
| ROICexc | 26.17% | ||
| ROICexgc | 34.98% | ||
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% | ||
| FCFM | 21.08% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
F-Score5
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 4.22 | ||
| Cap/Depr | 270.11% | ||
| Cap/Sales | 4.03% | ||
| Interest Coverage | 30.21 | ||
| Cash Conversion | 114.09% | ||
| Profit Quality | 101.56% | ||
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 | ||
| Altman-Z | 10.26 |
F-Score5
WACC9.36%
ROIC/WACC0.94
Cap/Depr(3y)384.02%
Cap/Depr(5y)409.93%
Cap/Sales(3y)4.85%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
EBIT growth 1Y8.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.79%
EBIT Next 3Y41.48%
EBIT Next 5Y38.45%
FCF growth 1Y635%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y478.63%
OCF growth 3YN/A
OCF growth 5YN/A
SHOCKWAVE MEDICAL INC / SWAV FAQ
What is the fundamental rating for SWAV stock?
ChartMill assigns a fundamental rating of 6 / 10 to SWAV.
What is the valuation status of SHOCKWAVE MEDICAL INC (SWAV) stock?
ChartMill assigns a valuation rating of 4 / 10 to SHOCKWAVE MEDICAL INC (SWAV). This can be considered as Fairly Valued.
What is the profitability of SWAV stock?
SHOCKWAVE MEDICAL INC (SWAV) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for SWAV stock?
The Price/Earnings (PE) ratio for SHOCKWAVE MEDICAL INC (SWAV) is 78.21 and the Price/Book (PB) ratio is 16.72.
Can you provide the financial health for SWAV stock?
The financial health rating of SHOCKWAVE MEDICAL INC (SWAV) is 7 / 10.